Phage protective agent, preparation method and application in phage preparation
By adding gelatin and L-ascorbic acid-2-phosphate composition to the phage diluent, the problem of reduced activity of phages during storage is solved, the stability and activity at room temperature is improved, and the shelf life is extended. It exhibits significant protective effect at high temperatures.
Patent Information
- Application Number
- CN202411088234.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-08
- Publication Date
- 2024-11-08
AI Technical Summary
Phages are susceptible to environmental factors during storage and transportation, resulting in reduced or lost activity, affecting the therapeutic effect, and the prior art is difficult to maintain the stability and activity of phages at room temperature, affecting the shelf life.
The phage protecting agent including gelatin and L-ascorbic acid-2-phosphate is used to adjust the pH and add it to the phage diluent, and the composition formed improves the stability of the phage at high temperature and is suitable for long-term storage at room temperature.
It significantly improves the stability and activity of phages at high temperatures, extends the shelf life, and ensures the stability and titer of long-term storage at room temperature. Especially at 37℃, 45℃ and 60℃, the storage effect is better than that used alone. Diluent.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of bacteriophage preservation, in particular to a bacteriophage protective agent, a preparation method and application in bacteriophage preparations. Background Art
[0002] Bacterial diseases seriously hinder the healthy development of animal husbandry. Antibiotics are easy to use and quick to take effect, playing an important role in treating bacterial diseases in animals. However, due to the abuse of antibiotics in animal husbandry, a large number of pathogens have developed drug resistance, destroying the ecological balance. In addition, chemical drug residues can also cause foodborne diseases in humans, posing a threat to human health.
[0003] Bacteriophage is a virus that can infect and lyse bacteria. It is widely present in the natural environment and living organisms and has strong host specificity. More importantly, the bacteriophage's bactericidal mechanism is not affected by the drug resistance of bacteria itself. Phages adsorb on the surface by recognizing specific receptors on the surface of bacteria, inject their own genetic material into the host for replication and assembly, and finally release progeny virus particles by lysing the host bacteria to achieve self-proliferation. Compared with antibiotics, bacteriophages have attracted much attention due to their high specificity, strong safety, few side effects, no residue after use, and low cost, and have become a star product for reducing and replacing antibiotics. Studies have shown that bacteriophages have good therapeutic effects in food, agriculture, poultry farming, aquaculture, and the treatment of human diseases. As an important weapon to deal with bacterial resistance, bacteriophages still have some problems that need to be solved in the actual use of bacteriophages: on the one hand, when preparing bacteriophage preparations, it is necessary to dilute the high-concentration bacteriophage stock solution. The diluent is also an important factor affecting the shelf life of the product. Poor selection of the diluent will rapidly reduce the activity of the bacteriophage and affect the application effect of the product. On the other hand, it is also particularly important to maintain the activity of phage products during transportation and storage after preparation. At present, phage preparations are rarely used for injection and are usually used in the form of spraying, splashing, etc. Due to the large dosage and high cost of freeze-dried phages, phages are usually stored in liquid form at 4-8°C. However, many breeding sites are remote, with long transportation times and unconditional low-temperature storage. As a living microorganism, phages are easily affected by environmental factors during storage and use, resulting in reduced or lost activity, affecting the therapeutic effect of phages. Therefore, in order to extend the shelf life of phages and facilitate storage and transportation, it is necessary to screen stable protective agents and diluents that maintain the stability and activity of phages at room temperature. Summary of the invention
[0004] The present invention provides a bacteriophage protective agent, a preparation method and application thereof in a bacteriophage preparation, which are used to improve the storage stability and activity of the bacteriophage and extend the shelf life.
[0005] In view of this, the scheme of the present invention is:
[0006] The first aspect of the present invention is to provide a phage protective agent, comprising a phage diluent, gelatin and L-ascorbic acid-2-phosphate; in terms of total mass percentage, the gelatin accounts for 1-2%, and the L-ascorbic acid-2-phosphate accounts for 0.5-1%.
[0007] Furthermore, the phage protective agent comprises, by mass percentage, the following components: Tris-HCl 0.4-0.7%, NaCl 0.6-0.9%, MgCl2 0.1-0.3%, CaCl2 0.01-0.1%, glutamic acid 0.1-0.3%, gelatin 1-2%, L-ascorbic acid-2-phosphate 0.5-1%, and the balance water.
[0008] Preferably, the phage protective agent comprises, by mass percentage, the following components: Tris-HCl 0.6%, NaCl 0.8-0.9%, MgCl2 0.2%, CaCl2 0.02%, glutamic acid 0.3%, gelatin 2%, L-ascorbic acid-2-phosphate 1%, and the balance water.
[0009] The second aspect of the present invention is to provide a method for preparing the phage protective agent described in the first aspect, which comprises first preparing a phage diluent and adjusting the pH, then adding gelatin and L-ascorbic acid-2-phosphate until the final concentration is reached and then sterilizing the mixture.
[0010] Further, the pH is adjusted to 7.4; and / or, HCl is used for pH adjustment.
[0011] The third aspect of the present invention is to propose the use of the phage protective agent described in the first aspect in the preparation of phage preparations.
[0012] The fourth aspect of the present invention is to provide a phage preparation, comprising a phage and the phage protecting agent described in the first aspect.
[0013] Furthermore, the bacteriophage is at least one of a Salmonella phage, an Escherichia coli phage or a Vibrio phage.
[0014] Furthermore, the phage is prepared by adding a phage suspension, wherein the volume ratio of the phage suspension to the protective agent is 1:1.
[0015] The fifth aspect of the present invention provides a method for preparing a phage preparation, 10. Adding a protective agent to the phage to obtain; the protective agent includes a phage diluent, gelatin and L-ascorbic acid-2-phosphate; in terms of total mass percentage, the gelatin accounts for 1-2%, and the L-ascorbic acid-2-phosphate accounts for 0.5-1%.
[0016] Compared with the prior art, the present invention has the following beneficial effects:
[0017] The phage protective agent of the present invention comprises a phage buffer, gelatin and L-ascorbic acid-2-phosphate, and each component can play a synergistic role to improve the stability of the phage at high temperature, and is suitable for long-term storage at room temperature. DETAILED DESCRIPTION
[0018] The technical solution of the present invention will be clearly and completely described below in conjunction with the preferred embodiments. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0019] In one embodiment, a phage protective agent is provided, including a phage diluent, gelatin and L-ascorbic acid-2-phosphate; in terms of total mass percentage, the gelatin accounts for 1-2%, and the L-ascorbic acid-2-phosphate accounts for 0.5-1%. The phage diluent can select a conventional dilution buffer used for phage dilution in the art, mainly including Tris, magnesium chloride and other ingredients. The gelatin and L-ascorbic acid-2-phosphate contained in the protective agent can play a synergistic role, improve the stability of the phage at high temperature, and are suitable for long-term storage at room temperature.
[0020] In a preferred embodiment, the phage diluent comprises Tris-HCl, NaCl, MgCl2, CaCl2, glutamic acid, and deionized water. The phage diluent protective agent comprises, by mass percentage, 0.4-0.7% Tris-HCl, 0.6-0.9% NaCl, 0.1-0.3% MgCl2, 0.01-0.1% CaCl2, 0.1-0.3% glutamic acid, 1-2% gelatin, 0.5-1% L-ascorbic acid-2-phosphate, and the balance water.
[0021] In a more preferred embodiment, the phage protecting agent comprises, by mass percentage, the following components: Tris-HCl 0.6%, NaCl 0.8-0.9%, MgCl2 0.2%, CaCl2 0.02%, glutamic acid 0.3%, gelatin 2%, L-ascorbic acid-2-phosphate 1%, and the balance water.
[0022] In one embodiment, a phage preparation is provided, the preparation comprising a protective agent and a phage suspension, the volume ratio of the phage suspension to the protective agent is 1:1, and the titer of the phage suspension is 10 8 -10 9PFU / m1. The bacteriophage is a Salmonella phage, an Escherichia coli phage or a Vibrio phage. In the following examples, the preparation process of the phage protective agent is as follows: 6.06g Tris-HCl, 8.76g NaCl, 2.04g MgCl2, 0.22g CaCl2 and 2.94g glutamic acid are weighed, dissolved in 950ml of deionized water, mixed evenly, adjusted to pH 7.4 with HCl, fixed to 1L, and then gelatin and L-ascorbic acid-2-phosphate are added to a final concentration of 2% and 1%, respectively, and the obtained product is obtained after sterilization.
[0023] Example 1 Screening of dilution protective agent
[0024] Specific implementation scheme of diluent:
[0025] 1) Preparation of phage suspension: Inoculate the host bacteria Sm2018052 into LB liquid medium and culture with shaking for 5 h (bacterial count is about 10 9 CFU / m1), inoculated with Salmonella phage at MOI = 0.01, continued to culture until the bacterial solution was completely clarified, centrifuged at 8000g for 10min, and collected the supernatant containing phage as phage suspension.
[0026] 2) Dilution: Dilute the phage suspension 1000 times with deionized water, physiological saline, and phage buffer, respectively. Place the sample at 37°C for a heat-accelerated storage experiment and regularly test the phage titer.
[0027] 3) Detection: Use the double-layer plate method to detect the phage titer after different storage times: Take 100 μl of phage suspension from each storage tube, dilute it 10 times with phage buffer solution, take 100 μl of the dilution from each tube, add 100 μl of host bacterial suspension (bacterial concentration is 10 9 CFU / ml), add 0.7% water agar after mixing, pour on LB solid plate, culture at 37℃ overnight, and count the number of plaques. Repeat three times for each sample.
[0028] The test results are shown in Table 1.
[0029] Table 1: Phage titers (PFU / mL) stored in different diluents
[0030]
[0031] From the results in Table 1, it can be seen that the Salmonella phage diluted with phage buffer still has relatively good activity after being stored at 37°C for 270 days. In contrast, the number of phage diluted with physiological saline decreased by more than two orders of magnitude after 90 days of storage, and the phage diluted with deionized water was the most unstable, decreasing by more than three orders of magnitude after 90 days of storage. Therefore, phage buffer is the best diluent.
[0032] Example 2 Screening of protective agent components
[0033] Specific implementation plan for screening protective agent components:
[0034] Four kinds of protective agent components were selected for single factor experiments, and the four kinds of sterile protective agent components were mixed evenly with Salmonella phages at a volume ratio of 1:1 to obtain Salmonella phage preparations. The final concentrations of each component after addition are shown in Table 2. In addition, a control group without adding protective agent was set up, for a total of 9 groups.
[0035] Table 2: Phage protectant components
[0036]
[0037]
[0038] (1) Preparation of phage suspension: The host bacteria Sm2018052 was inoculated into LB liquid medium and cultured with shaking for 5 h (the number of bacteria was about 10 9 CFU / m1), inoculate phages at MOI = 0.01, continue to culture until the bacterial solution is completely clear, centrifuge at 8000g for 10min, collect the supernatant containing phages as phage suspension, and dilute the phages to 10 with deionized water. 9 PFU / m1.
[0039] (2) Storage: The diluted phage suspension was mixed with each protective agent component in a 1:1 ratio. At the same time, the phage suspension was mixed with the phage buffer in a 1:1 ratio as a control. The samples were placed at 37°C for a heat-accelerated storage experiment. The phage titer was tested regularly to observe the effect of each group of protective agents.
[0040] (3) Detection: The double-layer plate method was used to detect the titer of phages after storage for different periods of time: 100 μl of phage suspension was taken from each storage tube, and 10 times serial dilutions were made with phage buffer solution. 100 μl of the dilution solution from each tube was taken and added with 100 μl of host bacterial suspension (bacterial concentration was 10 9 CFU / ml), add 0.7% water agar after mixing, pour on LB solid plate, culture at 37℃ overnight, count the number of plaques. Repeat three times for each sample, and calculate the average titer.
[0041] The test results are shown in Table 3:
[0042] Table 3: Effect of using different protective agents to preserve Salmonella phage
[0043]
[0044]
[0045] From the results in Table 3, it can be seen that after 100 days of storage at 37°C, the titer of the phage preparation in the trehalose group has dropped to 10 5 PFU / mL, the control group only decreased by 1 order of magnitude, indicating that trehalose had an impact on the activity of the phage, so this component should not be selected in the protective agent. After 60 days of constant temperature storage at 37°C, the phage titer in the glycerol group showed a clear downward trend, decreasing by more than 3 orders of magnitude, so glycerol was excluded from the protective agent. Compared with the control group, L-ascorbic acid-2-phosphate and gelatin groups showed a protective effect on the activity of phages. After 180 days of constant temperature storage at 37°C, no surviving phages were detected in the control group, and the titer of the 2% gelatin group still reached 10 6 PFU / mL, the 1% L-ascorbic acid-2-phosphate group was slightly worse, with a titer of 10 5 PFU / mL.
[0046] In summary, 2% gelatin and 1% L-ascorbic acid-2-phosphate were selected as the most effective stabilizing protective agents for phage preparations.
[0047] Example 3 Effect of the combination of diluent and stabilizing protective agent
[0048] Specific implementation scheme of the combination of diluent and stabilizing protective agent: Further, the phage buffer was used as a diluent of the stabilizing protective agent, and gelatin and L-ascorbic acid-2-phosphate were added to the diluent, with the final concentrations after addition being 2% and 1%, respectively. The added diluent was mixed with the Salmonella phage preparation at a volume ratio of 1:1, stored at a constant temperature of 37°C, and a deionized water group was used as a control. The test results are shown in Table 4.
[0049] Table 4: Effect of preserving Salmonella phage
[0050]
[0051] The results are shown in Table 4. After 6 months of storage at 37°C, the titer of phages preserved by the composition of the present invention was more stable than that of the control group, reaching 10 7 PFU / mL.
[0052] Example 4 Protective effect of phage preparations at high temperatures
[0053] Specific implementation scheme: Under sterile conditions, a diluent with a protective component was mixed with a Salmonella phage preparation at a volume ratio of 1:1, and stored at constant temperatures of 45°C and 60°C, respectively, and a deionized water group was used as a control. The test results are shown in Tables 5-6.
[0054] Table 5: Effect of storing Salmonella phage at 45°C
[0055]
[0056] The results are shown in Table 5. At a storage temperature of 45°C, the titer of the bacteriophage in the composition of the present invention began to decrease by one order of magnitude after 2 months of storage, and the titer dropped to 10 after 6 months of storage. 3 PFU / mL, while the phage titer of the control group began to decrease after 1 month of storage and was completely inactivated after 5 months. This shows that the composition of the present invention has a protective effect on phages.
[0057] Table 6: Effect of storing Salmonella phage at 60°C
[0058]
[0059] The results are shown in Table 6. At a storage temperature of 60°C, the titer of the bacteriophage in the composition of the present invention began to decrease by one order of magnitude after one month of storage, and decreased to 102 PFU / mL after five months of storage, and was completely inactivated after six months. The titer of the bacteriophage in the control group decreased by more than two orders of magnitude after one month of storage, and was completely inactivated after five months. This indicates that the composition of the present invention has a protective effect on bacteriophages.
[0060] Example 5 Effects of Different Phages on Accelerated Storage at 37°C
[0061] Specific implementation scheme: Under sterile conditions, the composition of the present invention was mixed with the Escherichia coli phage preparation and the Vibrio parahaemolyticus phage preparation at a volume ratio of 1:1, and stored at a constant temperature of 37°C. Deionized water was used as a control to compare the protective effects of the composition of the present invention on different phages. The test results are shown in Tables 7-8.
[0062] Table 7: Constant temperature accelerated test of Escherichia coli phage preparation
[0063]
[0064] The results are shown in Table 7. At a storage temperature of 37°C, the titer of the E. coli phage in the composition of the present invention began to decrease by one order of magnitude after 3 months of storage, and the titer dropped to 107 PFU / mL after 6 months of storage. The titer of the phage in the control group decreased by more than one order of magnitude after 1 month of storage, and was completely inactivated after 6 months. This indicates that the composition of the present invention has a protective effect on E. coli phage.
[0065] Table 8: Constant temperature accelerated experiment of Vibrio parahaemolyticus phage preparation
[0066]
[0067] The results are shown in Table 8. At 37°C, the phage titer of the control group decreased by more than one order of magnitude after one month of storage, and decreased to 10 after six months. 5 PFU / mL. The titer of Vibrio parahaemolyticus phage in the composition of the present invention began to decrease by one order of magnitude after 3 months of storage, and the titer dropped to 10 after 6 months of storage. 5 PFU / mL, which is 3 orders of magnitude higher than that of the control group, indicating that the composition of the present invention has a protective effect on Escherichia coli phage.
[0068] From the above experimental results, it can be seen that compared with the phages preserved in deionized water, the composition of the present invention has a better protective effect on different phages, and improves the stability of the phages by several orders of magnitude. The present invention contains a phage buffer, gelatin, and L-ascorbic acid-2-phosphate, and the preservation effect of the composition far exceeds the effect of preserving phages by a single factor, and at the same time proves that the protective agents of each component in the present invention can play a synergistic role and improve the stability of phages at high temperatures.
[0069] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.
Claims
1. Phage protectant, It is characterized in that It comprises a phage diluent, gelatin and L-ascorbic acid-2-phosphate; calculated by total mass percentage, the gelatin accounts for 1-2%, and the L-ascorbic acid-2-phosphate accounts for 0.5-1%.
2. The bacteriophage protective agent according to claim 1, It is characterized in that The phage protective agent comprises the following components by mass percentage: Tris-HCl 0.4-0.7%, NaCl 0.6-0.9%, MgCl 2 0.1-0.3%, CaCl 2 0.01-0.1%, glutamic acid 0.1-0.3%, gelatin 1-2%, L-ascorbic acid-2-phosphate 0.5-1%, and the balance water.
3. The bacteriophage protective agent according to claim 1, It is characterized in that The phage protective agent is composed of the following components by mass percentage: Tris-HCl 0.6%, NaCl 0.8-0.9%, MgCl 2 0.2%, CaCl 2 0.02%, glutamic acid 0.3%, gelatin 2%, L-ascorbic acid 2-phosphate 1%, and the balance water.
4. A method for preparing the bacteriophage protective agent according to any one of claims 1 to 3, It is characterized in that First, prepare the phage diluent and adjust the pH, then add gelatin and L-ascorbic acid-2-phosphate until the final concentration is reached and then sterilize to obtain the product.
5. The preparation method according to claim 4, It is characterized in that The pH is adjusted to 7.4; and / or, HCl is used for pH adjustment.
6. Use of the bacteriophage protective agent according to any one of claims 1 to 3 in the preparation of bacteriophage preparations.
7. Phage preparations, It is characterized in that It comprises a bacteriophage, and the bacteriophage protecting agent according to any one of claims 1 to 3.
8. The phage preparation according to claim 7, It is characterized in that The bacteriophage is at least one of a Salmonella phage, an Escherichia coli phage or a Vibrio phage.
9. The phage preparation according to claim 8, It is characterized in that The phage is prepared by adding a phage suspension, wherein the volume ratio of the phage suspension to the protective agent is 1:
1.
10. A method for preparing a bacteriophage preparation, It is characterized in that The protective agent is added to the bacteriophage to obtain the protective agent; the protective agent includes a bacteriophage diluent, gelatin and L-ascorbic acid-2-phosphate; based on the total mass percentage, the gelatin accounts for 1-2%, and the L-ascorbic acid-2-phosphate accounts for 0.5-1%.
Citation Information
Cited By
Fermentation culture process and application of broad-spectrum high-pathogenicity vibrio bacteriophage
CN119351351A
